S-892216 for COVID-19
S-892216 has been reported as potentially beneficial for
treatment of COVID-19. We have not reviewed these studies.
See all other treatments.
, P-1079. In Vitro and in Vivo Antiviral Activity of S-892216, a Second-Generation Oral 3CLpro Inhibitor against SARS-CoV-2, Open Forum Infectious Diseases, doi:10.1093/ofid/ofae631.1267
Abstract Background COVID-19 caused by SARS-CoV-2 remains a global public health concern. Although oral direct-acting antivirals for COVID-19 (such as molnupiravir, nirmatrelvir/ritonavir, ensitrelvir) were approved for clinical use, there are concerns about drug-drug interactions (DDI) and safety, so development of new therapeutics is needed. In this study, we describe enzyme inhibitory and antiviral activity of S-892216, a second-generation small molecular 3C-like protease (3CLpro) inhibitor. Methods The 3CLpro enzymatic assay was conducted by mass spectrometry system. In vitro antiviral activity was evaluated using VeroE6/TMPRSS2 cells and human airway epithelial cells (hAEC) following infection by several SARS-CoV-2 variants. In vivo efficacy was evaluated using Balb/c mice, intranasally infected with SARS-CoV-2, and S-892216 was orally administered. Results S-892216 showed high 3CLpro inhibitory activity (IC50 = 0.697 nmol/L) and exhibited in vitro antiviral activity against several SARS-CoV-2 strains, including Omicron variants (EC50 = 2.27-12.5 nmol/L in VeroE6/TMPRSS2 cells, EC90 = 2.31-2.41 nmol/L in hAECs). Furthermore, S-892216 suppressed lung virus titer in Balb/c mice infected with SARS-CoV-2 in a dose-dependent manner. Conclusion S-892216 has stronger 3CLpro inhibitory and antiviral activity than approved 3CLpro inhibitors and has been confirmed to be effective in vivo. Due to the strong antiviral activity of S-892216, it is suggested to be effective at low doses in clinical settings. DDI and safety will be evaluated in clinical trials. Disclosures Haruaki Nobori, PhD, Shionogi & Co., Ltd.: Employee|Shionogi & Co., Ltd.: Stocks/Bonds (Private Company) Sho Kawashima, Shionogi & Co., Ltd.: Employee Reiko Dodo, n/a, Shionogi & Co., Ltd.: Employee Yuki Maruyama, PhD, Shionogi & Co., Ltd.: Employee|Shionogi & Co., Ltd.: Stocks/Bonds (Private Company) Takayo Haruna, n/a, Shionogi & Co., Ltd.: Employee Keiichiro Hirai, PhD, Shionogi & Co., Ltd.: Employee Yuto Unoh, PhD, Shionogi & Co., Ltd.: Employee Kenji Nakahara, PhD, Shionogi & Co., Ltd.: Employee Shota Uehara, Ph.D., Shionogi & Co., Ltd.: Employee|Shionogi & Co., Ltd.: Stocks/Bonds (Private Company) ryosuke watari, n/a, Shionogi & Co., Ltd.: Employee tomoyuki kawachi, n/a, Shionogi & Co., Ltd.: Employee yuka Natsume, n/a, Shionogi & Co., Ltd.: Employee katsumoto hata, n/a, Shionogi & Co., Ltd.: Employee yukiko orita, n/a, Shionogi & Co., Ltd.: Employee kae fujisawa, n/a, Shionogi & Co., Ltd.: Employee tetsuya miyano, PhD, Shionogi & Co., Ltd.: Employee hideko kaneda, n/a, Shionogi..
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.